Longduoduo Company Limited (LDDD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 3 | 4 | 7 | 4 | - | 2 | - |
| Operating profit | $m | 1 | -0 | ||||||
| Net profit | $m | -0 | -8 | -0 | 1 | 0 | - | -0 | - |
| EPS reported | $ | 0.02 | -0.01 | ||||||
| Operating cashflow per share | $ | 0.01 | -0.01 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 0.01 | -0.01 | ||||||
| Free cash flow | $m | 0 | -0 | ||||||
| Net debt | $m | -2 | -1 | ||||||
| Book value equity | $m | 1 | 1 | ||||||
| Book value per share | $ | 0.04 | 0.02 | ||||||
| Number of shares | m | 30.01 | 30.02 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 326.14 | - | ||||||
| P/B LTM | x | 132.98 | 203.21 | ||||||
| P/S LTM | x | 36.95 | 70.25 | ||||||
| P/FCF LTM | x | 722.63 | -476.98 | ||||||
| EV/EBITDA LTM | x | 183.32 | -1,270.54 | ||||||
| EV/Sales LTM | x | 34.75 | 6.64 | ||||||
| Earnings Yield LTM | % | +0.31% | -2.30% | ||||||
| FCF Yield | % | +0.14% | -0.21% | ||||||
| Quality | |||||||||
| ROE | % | +38.87% | -36.07% | ||||||
| ROIC | % | +28.96% | -50.05% | ||||||
| Operating margin | % | +12.97% | -20.17% | ||||||
| Gross margin | % | +97.86% | +98.83% | ||||||
| FCF/Sales | % | +5.11% | -14.73% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -63.57% | - | ||||||
| Sales Growth YoY | % | -42.32% | -49.99% | ||||||
| Net Income Growth YoY | % | -63.33% | - | ||||||
| FCF Growth | % | -21.24% | - | ||||||
| Operating Profit Growth | % | -72.72% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 11.74 | -4.64 | ||||||
| Net Debt/EBITDA | x | -1.91 | 9.93 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -1.39 | -1.66 | ||||||
| Gross debt/equity | x | 0.02 | 0.09 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Longduoduo Company Limited, along with its associated entities, operates within the People's Republic of China, focusing on providing proactive health management and preventative medical services. The company's comprehensive suite of offerings includes health screenings, diverse treatment options, and specialized healthcare products, all aimed at reducing the likelihood of severe conditions such as myocardial infarction (heart attacks), cerebral infarction (strokes), hemiplegia (paralysis), and other cardiovascular and cerebrovascular diseases. These services are delivered through an extensive network of external collaborators, including independent healthcare providers, product vendors, and sales representatives. Additionally, Longduoduo features a range of advanced therapeutic interventions. These encompass meridian-regulating and consciousness-restoring techniques, a double blood purification process, immunological ozonated autohemotherapy, platelet-rich plasma therapy, relaxation techniques, vegetative nerve regulation, and microwave therapy. Established in 2020, the firm's primary operational base is located in Hohhot, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Longduoduo Company Limited, along with its associated entities, operates within the People's Republic of China, focusing on providing proactive health management and preventative medical services. The company's comprehensive suite of offerings includes health screenings, diverse treatment options, and specialized healthcare products, all aimed at reducing the likelihood of severe conditions such as myocardial infarction (heart attacks), cerebral infarction (strokes), hemiplegia (paralysis), and other cardiovascular and cerebrovascular diseases. These services are delivered through an extensive network of external collaborators, including independent healthcare providers, product vendors, and sales representatives. Additionally, Longduoduo features a range of advanced therapeutic interventions. These encompass meridian-regulating and consciousness-restoring techniques, a double blood purification process, immunological ozonated autohemotherapy, platelet-rich plasma therapy, relaxation techniques, vegetative nerve regulation, and microwave therapy. Established in 2020, the firm's primary operational base is located in Hohhot, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free